查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612567

生技药品市场：按来源、产品、适应症和最终用户分类 - 2025-2030 年全球预测

Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生技药品市场价值为4057.6亿美元，预计到2024年将达到4,305.9亿美元，复合年增长率为6.39%，到2030年将达到6263.4亿美元。

生技药品是製药业快速发展的一个领域，涵盖生物来源，例如疫苗、血液成分、基因疗法和单株抗体。慢性病的增加、生物技术的进步以及对标靶治疗的需求强调了对生技药品的需求。其应用范围涵盖癌症、类风湿性关节炎和多发性硬化症等疾病的治疗，并用于医院、研究机构和专科诊所。关键的成长要素包括基因工程和细胞疗法的持续创新，以及促进药物快速核准的强有力的监管支持。此外，製药公司和生技新兴企业之间的合作正在带来突破，特别是在精准医学和生物相似药（一类提供更便宜的替代疗法的药物）方面。治疗机会在于开发个人化治疗方法和提高生产扩充性以满足不断增长的需求。然而，生技药品市场面临研发成本高、製造流程复杂、法规要求严格等限制，往往导致上市时间较长。一个关键的挑战是保持产品的稳定性和一致性。市场参与企业的创新领域包括优化生物加工技术和利用人工智慧来简化药物发现和开发。强大的储存和配送基础设施对于克服低温运输的限制也至关重要。市场是动态的，进入障碍很高，成功创新的回报也很高。为了取得成功，公司应该注重策略联盟，共用技术，简化研发，并开拓医疗需求未被满足的新兴市场。驾驭此一局面需要平衡尖端科学发现与务实的供应链管理。

主要市场统计
基准年[2023] 4057.6亿美元
预计年份 [2024] 4305.9亿美元
预测年份 [2030] 6263.4亿美元
复合年增长率（%） 6.39%

市场动态：揭示快速发展的生技药品市场的关键市场洞察

供需的动态交互作用正在改变生技药品市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球慢性病盛行率上升
    • 对微创手术的需求和偏好日益增长
  • 市场限制因素
    • 与生技药品相关的治疗成本上升
  • 市场机会
    • 生医材料的持续进步改善慢性病的治疗
    • 不断扩大与生技药品相关的生产设施
  • 市场挑战
    • 生技药品复杂製造的可能性

波特五力：驾驭生技药品市场的策略工具

波特的五力架构是了解生技药品市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生技药品市场的外部影响

外部宏观环境因素在塑造生技药品市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解生技药品市场的竞争格局

生技药品市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生技药品市场供应商的绩效评估

FPNV定位矩阵是评估生技药品市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划生技药品市场的成功之路

对于希望加强在全球市场的影响力的公司来说，生技药品市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地慢性病盛行率正在上升
      • 对微创手术的需求和偏好日益增长
    • 抑制因素
      • 与生技药品相关的治疗成本上升
    • 机会
      • 生物材料的持续进步改善慢性病的治疗
      • 扩大生技药品相关生产设施
    • 任务
      • 生技药品复杂製造的可用性
  • 市场区隔分析
    • 资料来源：哺乳动物细胞更适合生产更大、更复杂的蛋白质
    • 适应症：由 COVID-19 大流行和癌症研究进展推动的肿瘤学和感染疾病的持续创新
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生技药品市场：依来源分类

  • 哺乳动物的
  • 微生物

第七章生技药品市场：副产品

  • 反义和RNAi疗法
  • 单株抗体
  • 重组激素或蛋白质
  • 疫苗

第八章生技药品市场的适应症

  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 感染疾病
  • 肿瘤学

第九章生技药品市场：依最终用户分类

  • 门诊手术中心
  • 医院

第10章美洲生技药品市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生技药品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的生技药品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准首个托珠单抗生物相似药 TOFIDENCE，改善自体免疫疾病治疗的可近性
    • 礼来公司扩大对爱尔兰生技药品製造工厂的投资
    • 山德士宣布对斯洛维尼亚新工厂进行重大投资
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen Inc.
  • BioPharm Laboratories, LLC
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Inc.
Product Code: MRR-4302AC72200D

The Biologics Market was valued at USD 405.76 billion in 2023, expected to reach USD 430.59 billion in 2024, and is projected to grow at a CAGR of 6.39%, to USD 626.34 billion by 2030.

Biologics, a rapidly expanding segment within the pharmaceutical industry, encompass a diverse range of products derived from living organisms, such as vaccines, blood components, gene therapy, and monoclonal antibodies. The increasing prevalence of chronic diseases, advancements in biotechnology, and the need for targeted therapies underscore the necessity of biologics. Their applications span across treating diseases like cancer, rheumatoid arthritis, and multiple sclerosis, serving hospitals, research institutions, and specialty clinics. Key growth influencers include ongoing innovations in genetic engineering and cell therapy, alongside robust regulatory support facilitating expedited drug approvals. Additionally, partnerships between pharmaceutical companies and biotech startups are yielding breakthroughs, particularly in precision medicine and biosimilars-a class of drugs offering more affordable therapeutic alternatives. Opportunities lie in developing personalized treatment approaches and enhancing production scalability to meet growing demand. However, the biologics market faces limitations such as high R&D costs, complex manufacturing processes, and stringent regulatory requirements which often prolong time-to-market transitions. A key challenge is maintaining product stability and consistency. For market players, innovative areas include optimizing bioprocessing techniques and harnessing artificial intelligence to streamline drug discovery and development. Robust infrastructure for storage and distribution is also vital to overcoming cold chain limitations. The market is dynamic, characterized by high barriers to entry but also high rewards for successful innovation. To thrive, businesses should focus on strategic alliances for technology sharing, enhancing R&D efficiencies, and exploring emerging markets with unmet medical needs. Navigating the biologics landscape requires balancing cutting-edge scientific discovery with pragmatic supply chain management-a challenge that, if met, promises significant growth potential in improving global health outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 405.76 billion
Estimated Year [2024] USD 430.59 billion
Forecast Year [2030] USD 626.34 billion
CAGR (%) 6.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Market

The Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases worldwide
    • Growing need and preference for minimally invasive procedures
  • Market Restraints
    • High cost of treatment associated with biologics
  • Market Opportunities
    • Ongoing advancements in biomaterials improving the treatment of chronic disorders
    • Rising expansion of manufacturing facilities associated with biologics
  • Market Challenges
    • Availability of complex manufacturing of biologics

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Market

A detailed market share analysis in the Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Market

A strategic analysis of the Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Product, market is studied across Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins, and Vaccines.
  • Based on Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, Infectious Diseases, and Oncology.
  • Based on End-user, market is studied across Ambulatory Surgical Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need and preference for minimally invasive procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • 5.1.3.2. Rising expansion of manufacturing facilities associated with biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of complex manufacturing of biologics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Mammalian cells are preferable for producing larger and more complex proteins
    • 5.2.2. Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Market, by Product

  • 7.1. Introduction
  • 7.2. Antisense & RNAi Therapeutics
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Hormones or Proteins
  • 7.5. Vaccines

8. Biologics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Infectious Diseases
  • 8.6. Oncology

9. Biologics Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Biologics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
    • 13.3.2. Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
    • 13.3.3. Sandoz Announces Major Investment in New Biologics Facility in Slovenia
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Biogen Inc.
  • 7. BioPharm Laboratories, LLC
  • 8. Bristol Myers Squibb Company
  • 9. Catalent, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech, Inc.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Innovent Biologics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Thermo Fisher Scientific Inc.
  • 21. Vertex Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023